Back to Maryland

SB0435 • 2026

Public Health - Medetomidine and Xylazine Consumer Protection Act

Public Health - Medetomidine and Xylazine Consumer Protection Act

Passed Legislature

This bill passed both chambers and reached final enrollment, even if later executive action is not shown here.

Sponsor
Senator Folden
Last action
2026-03-25
Official status
In the Senate - Laid Over (Senator Ready) Adopted
Effective date
2026-10-01

Plain English Breakdown

Using official source text because the generated explanation was unavailable or could not be confirmed against the official bill text.

Public Health - Medetomidine and Xylazine Consumer Protection Act

Prohibiting a retailer from distributing, selling, or exposing for sale a medetomidine product or xylazine product unless the purchaser provides proof the intended use is for institutional, veterinary, or scientific purposes; prohibiting a retailer from distributing, selling, or exposing for sale a medetomidine or xylazine product to an individual under the age of 21 years; requiring a retailer that prepares, distributes, sells, or exposes for sale a medetomidine or xylazine product to maintain certain records; etc.

What This Bill Does

  • Prohibiting a retailer from distributing, selling, or exposing for sale a medetomidine product or xylazine product unless the purchaser provides proof the intended use is for institutional, veterinary, or scientific purposes; prohibiting a retailer from distributing, selling, or exposing for sale a medetomidine or xylazine product to an individual under the age of 21 years; requiring a retailer that prepares, distributes, sells, or exposes for sale a medetomidine or xylazine product to maintain certain records; etc.

Limits and Unknowns

  • This entry is temporarily using official source text because the generated explanation could not be confirmed against the official bill text during the last sync.

Amendments

These notes stay tied to the official amendment files and metadata from the legislature.

983727/1

None

Favorable with Amendments { 983727/1

Plain English: AMENDMENTS TO SENATE BILL 435 (First Reading File Bill) AMENDMENT NO.

  • AMENDMENTS TO SENATE BILL 435 (First Reading File Bill) AMENDMENT NO.
  • 1 On page 1, in line 2, strike “ Public Health” and substitute “ Criminal Law – Schedule III Controlled Dangerous Substances ”; in the same line, strike “Consumer Protection Act ”; strike beginning with “prohibiting” in line 3 down through “Fund” in line 11 and substitute “ establishing medetomidine and xylazine as Schedule III controlled dangerous substances under the Maryland Controlled Dangerous Substances Act ”; in line 12, strike “products”; and strike in their entirety lines 13 through 28, inclusive, and substitute: “BY repealing and reenacting, with amendments, Article - Criminal Law Section 5-404 Annotated Code of Maryland (2021 Replacement Volume and 2025 Supplement)”.
  • AMENDMENT NO.
  • 2 On pages 2 through 4, strike in their entirety the lines beginning with line 3 on page 2 through line 2 on page 4, inclusive, and substitute: “Article – Criminal Law 5–404.

Bill History

  1. 2026-04-13 Senate

    Favorable with Amendments Report by Finance

  2. 2026-03-25 Senate

    Favorable with Amendments { 983727/1

  3. 2026-03-25 Senate

    Motion Laid Over (Senator Ready) Adopted

  4. 2026-02-03 Senate

    Hearing 2/11 at 2:00 p.m.

  5. 2026-01-30 Senate

    First Reading Finance

  6. Maryland General Assembly

    Text - First - Public Health - Medetomidine and Xylazine Consumer Protection Act

  7. Maryland General Assembly

    Vote - Senate - Committee - Finance

Official Summary Text

Prohibiting a retailer from distributing, selling, or exposing for sale a medetomidine product or xylazine product unless the purchaser provides proof the intended use is for institutional, veterinary, or scientific purposes; prohibiting a retailer from distributing, selling, or exposing for sale a medetomidine or xylazine product to an individual under the age of 21 years; requiring a retailer that prepares, distributes, sells, or exposes for sale a medetomidine or xylazine product to maintain certain records; etc.

Current Bill Text

Read the full stored bill text
EXPLANATION: CAPITALS INDICATE MATTER ADDED TO EXISTING LAW.
[Brackets] indicate matter deleted from existing law.
*sb0435*

SENATE BILL 435
J1 6lr2869
SB 875/25 – FIN CF HB 417
By: Senator Folden
Introduced and read first time: January 30, 2026
Assigned to: Finance

A BILL ENTITLED

AN ACT concerning 1

Public Health – Medetomidine and Xylazine Consumer Protection Act 2

FOR the purpose of prohibiting a retailer from distributing, selling, or exposing for sale a 3
medetomidine product or a xylazine product unless the purchaser p rovides to the 4
retailer certain proof; prohibiting a retailer from distributing, selling, or exposing for 5
sale a medetomidine product or a xylazine product to an individual under a certain 6
age; requiring a retailer that prepares, distributes, sells, or exp oses for sale a 7
medetomidine product or a xylazine product to maintain certain records; requiring 8
the Maryland Department of Health to remit all civil penalties collected for a 9
violation of certain provisions of this Act to the Comptroller to be deposited in the 10
Maryland Substance Abuse Fund; and generally relating to medetomidine and 11
xylazine products. 12

BY repealing and reenacting, without amendments, 13
Article – Health – General 14
Section 8–6A–01(a) 15
Annotated Code of Maryland 16
(2023 Replacement Volume and 2025 Supplement) 17

BY repealing and reenacting, with amendments, 18
Article – Health – General 19
Section 8–6A–01(b)(3) 20
Annotated Code of Maryland 21
(2023 Replacement Volume and 2025 Supplement) 22

BY adding to 23
Article – Health – General 24
Section 21 –2G–01 thr ough 21 –2G–03 to be under the new subtitle “Subtitle 2G. 25
Medetomidine and Xylazine Consumer Protection Act” 26
Annotated Code of Maryland 27
(2023 Replacement Volume and 2025 Supplement) 28
2 SENATE BILL 435

SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND, 1
That the Laws of Maryland read as follows: 2

Article – Health – General 3

8–6A–01. 4

(a) In this section, “Fund” means the Maryland Substance Abuse Fund. 5

(b) (3) The Fund consists of [the]: 6

(I) THE fee required under § 6 –229 of the Criminal Procedure 7
Article[, money]; 8

(II) CIVIL PENALTIES COLLE CTED AND REMITTED TO THE 9
COMPTROLLER UNDER § 21–2G–02(E) OF THIS ARTICLE; 10

(III) MONEY appropriated in the State budget to the Fund[, all]; 11

(IV) ALL earnings from investment of money in the Fund [,]; and 12
[other] 13

(V) ANY OTHER money accepted for the benefit of the Fund from a 14
governmental or private source. 15

SUBTITLE 2G. MEDETOMIDINE AND XYLAZINE CONSUMER PROTECTION ACT. 16

21–2G–01. 17

(A) IN THIS SUBTITLE THE FOLLOWING WORDS HAVE THE MEANINGS 18
INDICATED. 19

(B) “MEDETOMIDINE PRODUCT ” MEANS A PRODUCT CONT AINING ANY 20
AMOUNT OF MEDETOMIDINE. 21

(C) (1) “RETAILER” MEANS A PERSON THAT: 22

(I) SELLS, PREPARES, OR MAINTAINS MEDETOM IDINE 23
PRODUCTS OR XYLAZINE PRODUCTS; OR 24

(II) ADVERTISES, REPRESENTS, OR HOLDS ITSELF OUT AS 25
SELLING, PREPARING, OR MAINTAINING MEDETOMIDINE PRODUCTS AND XYLAZINE 26
PRODUCTS. 27
SENATE BILL 435 3

(2) “RETAILER” INCLUDES A MANUFACTU RER, A WHOLESALER , A 1
CORPORATION, A PARTNERSHIP , A LIMITED LIABILITY COMPANY, A FIRM , AN 2
ONLINE PLATFORM, OR ANY OTHER BUSINESS ENTITY DOING BUSINESS WITHIN THE 3
STATE. 4

(D) “XYLAZINE PRODUCT” MEANS A PRODUCT CONTAINING ANY AMOUNT OF 5
XYLAZINE. 6

21–2G–02. 7

(A) A RETAILER MAY NOT DISTRIBUTE OR SELL A MEDETOMIDINE PRODUCT 8
OR XYLAZINE PRODUCT UNLESS THE PURCHASER PROVIDES TO THE RETA ILER 9
PROOF OF THE PURCHASER ’S INTENT TO USE THE MEDETOMIDINE PRODUCT OR 10
XYLAZINE PRODUCT FOR AN INSTITUTIONAL , VETERINARY, OR SCIENTIFIC 11
PURPOSE. 12

(B) A RETAILER MAY NOT DIS TRIBUTE, SELL, OR EXPOSE FOR SALE A 13
MEDETOMIDINE PRODUCT OR A XYLAZINE PRODUCT TO AN INDIVIDUAL UNDER THE 14
AGE OF 21 YEARS. 15

(C) A RETAILER THAT PREPAR ES, DISTRIBUTES, SELLS, OR EXPOSES FOR 16
SALE A MEDETOMIDINE PRODUCT OR A XYLAZIN E PRODUCT SHALL MAIN TAIN 17
RECORDS OF ALL SALES, INCLUDING A COPY OF: 18

(1) THE IDENTIFICATION USED AS PROOF OF THE PURCHASER’S AGE; 19
AND 20

(2) EACH DOCUMENT OR OTHE R MATERIAL USED AS P ROOF OF THE 21
PURCHASER’S INTENDED USE. 22

(D) A RETAILER THAT VIOLAT ES THIS SECTION IS S UBJECT TO A CIVIL 23
PENALTY NOT EXCEEDING: 24

(1) $3,000 FOR A FIRST VIOLATION; OR 25

(2) $6,500 FOR EACH SUBSEQUENT VIOLATION. 26

(E) THE DEPARTMENT SHALL REMI T ALL CIVIL PENALTIE S COLLECTED 27
UNDER SUBSECTION (D) OF THIS SECTION TO THE COMPTROLLER TO BE DEPOSITED 28
IN THE MARYLAND SUBSTANCE ABUSE FUND. 29

21–2G–03. 30
4 SENATE BILL 435

THE DEPARTMENT SHALL ADOP T REGULATIONS TO C ARRY OUT THIS 1
SUBTITLE. 2

SECTION 2. AND BE IT FURTHER ENACTED, That this Act shall take effect 3
October 1, 2026. 4